The "Albumin Effect" and drug glucuronidation: Bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities

被引:136
|
作者
Rowland, Andrew
Knights, Kathleen M.
Mackenzie, Peter I.
Miners, John O.
机构
[1] Flinders Univ S Australia, Dept Clin Pharmacol, Adelaide, SA 5001, Australia
[2] Flinders Med Ctr, Adelaide, SA, Australia
关键词
D O I
10.1124/dmd.108.021105
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Bovine serum albumin (BSA) and fatty acid-free human serum albumin (HSAFAF) reduce the Km values for UGT2B7 substrates by sequestering inhibitory long-chain fatty acids released by incubations of human liver microsomes (HLM) and HEK293 cells expressing this enzyme. However, the scope of the "albumin effect" is unknown. In this investigation we characterized the effects of albumin on the kinetics of 4-methylumbelliferone (4MU) glucuronidation by UDP-glucuronosyltransferase (UGT) 1A1, 1A6, and 1A9, and propofol (PRO) glucuronidation by UGT1A9 and HLM. BSA and HSAFAF, but not human serum albumin, reduced the Km values for 4MU and PRO glucuronidation by UGT1A9. For example, HSAFAF (2%) reduced the Km values for 4MU and PRO glucuronidation from 13.4 to 2.9 and 41 to 7.2 mu M, respectively. Similarly, HSAFAF (2%) reduced the Km for PRO glucuronidation by HLM from 127 to 10.6 mu M. Arachidonic, linoleic, and oleic acids and a mixture of these decreased the rates of 4MU and PRO glucuronidation by UGT1A9. Km values for these reactions were increased 3- to 6-fold by the fatty acid mixture. Inhibition was reversed by the addition of BSA (2%). Extrapolation of kinetic constants for PRO glucuronidation by HLM in the presence of HSAFAF predicted in vivo hepatic clearance within 15%. Fatty acids had no effect on 4MU glucuronidation by UGT1A1 and UGT1A6 but, paradoxically, all forms of albumin altered the kinetic model for 4MU glucuronidation by UGT1A6 (from Michaelis-Menten to two-site). Only BSA caused a similar effect on 4MU glucuronidation by UGT1A1. It is concluded that BSA and HSAFAF reduce the Km values of only those enzymes inhibited by long-chain unsaturated fatty acids.
引用
收藏
页码:1056 / 1062
页数:7
相关论文
共 50 条
  • [21] UDP-glucuronosyltransferase in the rat olfactory bulb: Identification of the UGT1A6 isoform and age-related changes in 1-naphthol glucuronidation
    Gradinaru, D
    Suleman, FG
    Leclerc, S
    Heydel, JM
    Grillasca, JP
    Magdalou, J
    Minn, A
    NEUROCHEMICAL RESEARCH, 1999, 24 (08) : 995 - 1000
  • [22] Genetic polymorphism in the human UGT1A6 UDP-glucuronosyltransferase: Pharmacological implications.
    Ciotti, M
    Marrone, A
    Owens, IS
    AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (04) : A249 - A249
  • [23] Preparation of a Specific Monoclonal Antibody against Human UDP-Glucuronosyltransferase (UGT) 1A9 and Evaluation of UGT1A9 Protein Levels in Human Tissues
    Oda, Shingo
    Nakajima, Miki
    Hatakeyama, Masahiko
    Fukami, Tatsuki
    Yokoi, Tsuyoshi
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (08) : 1620 - 1627
  • [24] UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics:: I.: Identification of polymorphisms in the 5′-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation
    Krishnaswamy, S
    Hao, Q
    Al-Rohaimi, A
    Hesse, LM
    von Moltke, LL
    Greenblatt, DJ
    Court, MH
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 313 (03): : 1331 - 1339
  • [25] Glucuronidation of fenamates: Kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and ZB7
    Gaganis, Paraskevi
    Miners, John O.
    Knights, Kathleen M.
    BIOCHEMICAL PHARMACOLOGY, 2007, 73 (10) : 1683 - 1691
  • [26] UDP-glucuronosyltransferase 1A1 (UGT1A1) gene haplotypes and their effect on serum bilirubin concentration in healthy Indian adults
    D'Silva, Selma
    Colah, Roshan B.
    Ghosh, Kanjaksha
    Mukherjee, Malay B.
    GENE, 2013, 513 (01) : 36 - 39
  • [27] In silico and in vitro Approaches to Elucidate the Thermal Stability of Human UDP-glucuronosyltransferase (UGT) 1A9
    Fujiwara, Ryoichi
    Nakajima, Miki
    Yamamoto, Tetsunori
    Nagao, Hidemi
    Yokoi, Tsuyoshi
    DRUG METABOLISM AND PHARMACOKINETICS, 2009, 24 (03) : 235 - 244
  • [28] Differences in the regulation of the UGT1A1, UGT1A6, UGT2B4 and UGT2B7 genes in human liver and small intestine define tissue specific and interindividual glucuronidation activities.
    Strassburg, CP
    Kneip, S
    Topp, J
    Obermayer-Straub, P
    Turkey, RH
    Manns, MP
    HEPATOLOGY, 2000, 32 (04) : 330A - 330A
  • [29] Heterodimerization of Human UDP-Glucuronosyltransferase 1A9 and UDP-Glucuronosyltransferase 2B7 Alters Their Glucuronidation Activities
    Xue, Jia
    Yin, Jiayi
    Nie, Jing
    Jiang, Huidi
    Zhang, Haitao
    Zeng, Su
    DRUG METABOLISM AND DISPOSITION, 2023, 51 (11) : 1499 - 1507
  • [30] Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications
    Ciotti, M
    Marrone, A
    Potter, C
    Owens, IS
    PHARMACOGENETICS, 1997, 7 (06): : 485 - 495